1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Pharmaceutical Market India 2014-2020, Formulations, Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services (CRAMS), Biosimilars, Generics & Vaccines

“PHARMACEUTICAL MARKET INDIA 2014-2020, Formulations, Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services (CRAMS), Biosimilars, Generics & Vaccines” by Kelly Scientific Publications is a comprehensive report on the pharmaceutical and biotechnology industry in India and its impact on international markets. This report scrutinises top Indian pharmacos and their battle within domestic and international therapeutic markets. The business environment in which they compete is analysed as are key drivers, constraints, challenges and opportunities.

The Indian pharmaceutical market is set to become the eight largest pharma market globally by 2015. In 2012 it was worth $x billion according to the India Brand Equity Foundation (IBEF). It is forecast to reach at least $x billion by 2020 and increase its dominance as a leading player in Asia. It is predicted that the Indian pharma market will be a significant global competitor by 2020 with an expected worth of up to $x billion. This depends on the optimisation of the following submarkets: public health, generics, consumer healthcare drugs, biologics, vaccines and patented products.

This report describes the current therapeutics that are propelling the pharmaceutical and biotechnology markets in India. It examines the current economic climate and how India compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.

This study reveals market figures of the overall Indian pharmaceutical market and sub-markets. It is supported by 333 figures and tables over 183 pages and the reader has the opportunity to re-use and referene these exhibits in their own reports and presentations. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.

The study also provides a comprehensive financial and product review of key players in the pharmaceutical and biotechnology industry in India. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.

In summary, the Indian biopharmaceutical market has huge opportunities for growth. This industry will significantly affect the international healthcare market and has enormous potential for investment.

Table Of Contents

Pharmaceutical Market India 2014-2020, Formulations, Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services (CRAMS), Biosimilars, Generics and Vaccines
Pharmaceutical Market India 2014-2020, Formulations, Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services (CRAMS), Biosimilars, Generics and Vaccines
1.0 Summary 9
1.1 Objectives of Report 9
1.2 Scope of Study 10
1.3 Data Sources and Methodology 10
1.4 Key Findings and Observations 11
1.5 Executive Summary 11
2.0 Epidemiology and Disease Overview 15
2.1 Cardiovascular Disease 19
2.2 Infectious Disease 20
2.3 Respiratory Infections 21
2.4 Tuberculosis 23
2.5 HIV 28
2.6 Hepatitis 29
2.7 Typhoid Fever 30
2.8 Dengue Fever 30
2.9 Diabetes 30
2.10 Cancer 32
2.11 Chronic Respiratory Disease- Asthma and COPD 36
3.0 Twelfth Five Year Plan - A Boost for Scientific Research and Development 38
4.0 Economic and Business Environment 40
4.1 Economic Indicators, Trade Policy and Merchandise and Commercial Trade Statistics 40
4.2 Gross Domestic Product of India, Historic and Projection Analysis 42
4.3 Global and India Economic Outlook 2010-2013 43
4.4 Indian Economic Outlook in Comparison to Advanced Economies (US, Europe) 45
5.0 Indian Pharmaceutical Industry 48
5.1 Overview 48
5.2 Evolution of Indian Pharmaceutical Industry 49
5.3 Pharmaceutical Export Market 50
5.4 Formulations Market 52
5.5 Active Pharmaceutical Ingredient Market 53
5.6 Biosimilar Market 53
5.7 Contract Research and Manufacturing Service (CRAMS) 54
5.8 Indian Pharmaceutical Industry Market 57
5.9 Evaluation of Market Share by Therapeutic Area 62
5.10 Indian Biotechnology Industry 63
5.11 Generic Drug Market 65
5.12 Vaccine Industry in India 65
5.13 Key Players 66
5.14 RandD Spending on the Increase 68
5.15 Important Market Trends Within the Indian Pharmaceutical Industry 69
6.0 Indian Pharmaceutical Company Profiles and Financial Data 71
6.1 Aurobindo Pharma 71
6.2 Bharat Serums and Vaccines Ltd 79
6.3 Biocon Biopharmaceuticals 81
6.4 Cipla 90
6.5 Divis Laboratories 94
6.6 Dr Reddy's Laboratories 96
6.7 Lupin 102
6.8 Mankind Pharma 114
6.9 Panacea Biotech 119
6.10 Piramal Group 127
6.11 Ranbaxy Laboratories 133
6.12 Reliance Life Sciences 142
6.13 Serum Institute of India 144
6.14 Sun Pharmaceuticals 148
6.15 Zydus Cadila 154
7.0 SWOT Analysis of Indian Pharmaceutical Market 161
7.1 Growth Factors 161
7.2 Strengths of Indian Pharmaceutical Industry 163
7.3 Main Weaknesses 164
7.4 Significant Opportunities within the Indian Pharmaceutical Industry 165
7.5 Threats and Considerations 166
8.0 Company Directory and Key People 167
8.1 Aurobindo Pharma 167
8.2 Bharat Serums and Vaccines Ltd 168
8.3 Biocon Biopharmaceuticals 169
8.4 Cipla 171
8.5 Divis laboratories 171
8.6 Dr Reddy's Laboratories 173
8.7 Lupin 175
8.8 Panacea Biotech 176
8.9 Reliance Life Sciences 178
9.0 Appendix 180
9.1 Comprehensive List of Pharmaceutical Company's in India 180

List of Exhibits

Exhibit 2.1: Key Statistics: India 15
Exhibit 2.2: National Expenditure on Health (Indian Rupee) 2000 - 2011 15
Exhibit 2.3: Top Ten Causes of Mortality in India 2008-2030 17
Exhibit 2.4: Estimated Number of Deaths Due to Most Prevalent Disease States, India 17
Exhibit 2.5: Historic and Projected Death Rates Due to Cardiovascular and Cancer, India 2004-2030 18
Exhibit 2.6: Trend of Communicable and Non-Communicable Disease Burden in Developing World 18
Exhibit 2.7: Cardiovascular Mortality by Indian State 19
Exhibit 2.8: Factors Contributing to High Prevalence of Cardiovascular Disease in India 20
Exhibit 2.9: Distribution of Cause of Death in Children under Five, India 20
Exhibit 2.10: Global Incidence of Childhood Clinical Pneumonia 22
Exhibit 2.11: Global Distribution of Deaths from Pneumonia and other Causes in Children 22
Exhibit 2.12: Revised National Tuberculosis Control Program (RNTCP) Statistics 2005-Present 23
Exhibit 2.13: Estimated Global Tuberculosis Incidence Rates 24
Exhibit 2.15: Estimated Global HIV Prevalence in New TB Cases 24
Exhibit 2.14: India TB Statistics by State, Population Covered, Diagnosis, Treatment Relapse and HIV Co-infection 25
Exhibit 2.16: Number of MDR-TB Cases Estimated to Occur Among Notified Pulmonary TB Cases 2011 26
Exhibit 2.17: Countries That Have Notified of at Least One XDR-TB Case 26
Exhibit 2.18: TB Vaccine Development Pipeline 2012 28
Exhibit 2.19: HIV Prevalence in India 2004-2009 29
Exhibit 2.20: Routes of HIV Transmission in India 29
Exhibit 2.21: Global Hepatitis E Virus Endemicity 30
Exhibit 2.22: Prevalence of Diabetes by Indian Region 31
Exhibit 2.23: Global Prevalence of Undiagnosed Diabetes 31
Exhibit 2.24: Incidence and Mortality Rates for Top Sixteen Cancers in India - Both Sexes 32
Exhibit 2.25: Prevalence of Cancer Cases and Deaths in India, Male and Female 33
Exhibit 2.26: Incidence and Mortality Rates for Top Sixteen Cancers in India - Men 33
Exhibit 2.27: Incidence and Mortality Rates for Top Sixteen Cancers in India - Women 34
Exhibit 2.28: Percentage Incidence Distribution of the most Frequent Cancers in India, Both Sexes 34
Exhibit 2.28: Percentage Mortality Distribution of the most Frequent Cancers in India, Both Sexes 35
Exhibit 2.29: Five Year Prevalence and Incidence of Top Twenty Cancer's in India 35
Exhibit 2.30: Mortality Rate (per 100,000) Attributable to Chronic Obstructive Pulmonary Disease Globally 36
Exhibit 3.1: India's Twelve Year Plan - Key Points in Relation to Science Research and Development 39
Exhibit 3.2: Budget for Specific Scientific Departments under India's Twelfth Five Year Plan 39
Exhibit 4.1: World Trade Organisation Basic Indicators on India 40
Exhibit 4.2: World Trade Organisation Trade Policy of India 40
Exhibit 4.3: World Trade Organisation Merchandise Trade Statistics: India 41
Exhibit 4.4: World Trade Organisation Commercial Services Trade Statistics: India 41
Exhibit 4.5: World Trade Organisation Industrial Property Statistics: India 41
Exhibit 4.6: India GDP Figures 2011-2018 42
Exhibit 4.7: India Health Expenditure as a Percentage of GDP 2000-2010 42
Exhibit 4.8: Global, Emerging Market and Developing Countries Economic Growth Change 2010-2013 43
Exhibit 4.9: Global, Emerging Market and Developing Countries and India Economic Growth Change 2010-2013 43
Exhibit 4.10: Global, Emerging Market, Developing Countries and Russia Economic Growth Change 2010-2013 44
Exhibit 4.11: Global, Emerging Market and Developing Countries and China Economic Growth Change 2010-2013 44
Exhibit 4.12: Global, Emerging Market and Developing Countries and Brazil Economic Growth Change 2010-2013 44
Exhibit 4.13: Global, US and Germany Economic Growth 2010-2013 45
Exhibit 4.14: US and UK Gross Domestic Product per capita Forecast 2010-2017 45
Exhibit 4.15: Global, France and Italy Economic Growth 2010-2013 46
Exhibit 4.16: France, Germany and Italy Gross Domestic Product per capita Forecast 2010-2017 46
Exhibit 4.17: Global, UK and Spain Economic Growth 2010-2013 47
Exhibit 4.18: Global, Japan and Canada Economic Growth 2010-2013 47
Exhibit 4.19: India, Brazil and China Gross Domestic Product per capita Forecast 2010-2017 47
Exhibit 5.1: Four Major Areas of the Indian Pharmaceutical Industry 48
Exhibit 5.2: Evolution Timeline of The Indian Pharmaceutical Industry 49
Exhibit 5.3: Indian Pharmaceutical Industry IPM and Exports 2003-2015 50
Exhibit 5.4: Indian Pharmaceutical Industry Bulk Drug Exports 2003-2015 50
Exhibit 5.5: Top 50 Exporting Pharmaceutical Companies in India 51
Exhibit 5.6: Indian Pharmaceutical Industry Formulation Exports 2003-2015 52
Exhibit 5.7: Indian Pharmaceutical Industry Domestic Formulations 2003-2015 52
Exhibit 5.8: Geographic Distribution of India's Active Pharmaceutical Ingredient Exports, 2012 53
Exhibit 5.9: Current Trends of the Global Biosimilar Market 54
Exhibit 5.10: Main Therapeutic Areas of the Future Biosimilar Market 54
Exhibit 5.11: Market Share ($ Billions) of Contract Manufacturing and Research within Indian CRAMS Industry 55
Exhibit 5.12: Market Share (Percentage) of Contract Manufacturing and Research within Indian CRAMS Industry 55
Exhibit 5.13: Indian Contract Research and Manufacturing Services (CRAMS) Market 2010-2015 56
Exhibit 5.14: Drivers and Resistors of the Indian CRAMS/CMO Industry 56
Exhibit 5.15: Advantages of Contract Research Organizations in India 56
Exhibit 5.16: Challenges of Contract Research Organizations in India 57
Exhibit 5.17: Areas of Growth and Potential for Indian Contract Research Organisation's 57
Exhibit 5.18: Indian Pharmaceutical Market Revenue 2005-2020 57
Exhibit 5.19: Generic Drug, Over the Counter and Patened Drug Sub-Market Revenue Share 58
Exhibit 5.20: India's Pharmaceutical Market Share by Value in the Asia-Pacific Region 58
Exhibit 5.21: Leading Players of the Indian Pharmaceutical Market 59
Exhibit 5.22: Top 20 Biotechnology Companies in India by Revenue FY2013 59
Exhibit 5.23: India - Significant Economic Indicators 60
Exhibit 5.24: Positive Factors Influencing the Indian Pharmaceutical Market 60
Exhibit 5.25: Quantitative Market Share of Acute and Chronic Therapy in India 61
Exhibit 5.26: Multinational Company Penetration into Indian Pharmaceutical Market 61
Exhibit 5.27: Key Factors Influencing Leading Player Position in India Pharma Market 62
Exhibit 5.28: Partnerships Between International Pharmaco's and Domestic API Partners 62
Exhibit 5.29: Indian Pharmaceutical Market Share (%) by Therapeutic Area 2013-Table Format 62
Exhibit 5.30: Indian Pharmaceutical Market Share (%) by Therapeutic Area 2013- Pie Chart Format 62
Exhibit 5.31: Indian Pharmaceutical Market Share (%) by Therapeutic Area 63
Exhibit 5.32: Top Five Fastest Growing Indian Pharma Market Segments 63
Exhibit 5.33: Top Biotechnology Companies by Revenue FY2013 (Barchart) 64
Exhibit 5.34: Top 20 Biotechnology Companies in India by Revenue FY2013 Table 64
Exhibit 5.35: Top Five Emerging Opportunities within the Indian Pharmaceutical Market 65
Exhibit 5.36: Top Five Indian Vaccine Manufacturers 65
Exhibit 5.37: Top Pharmaceutical Companies within the Indian Pharmaceutical Market by Market Share and Revenue 66
Exhibit 5.38: Percentage Market Share of Leading Players in the Indian Pharmaceutical Market 66
Exhibit 5.39: Revenue Reported from Leading Players of Indian Pharmaceutical Market 2012 67
Exhibit 5.40: Revenue Reported from Leading Players of Indian Pharmaceutical Market 2013 67
Exhibit 5.41: RandD Investment Comparison of Top Indian Pharmaco's 2010 Vs 2013 68
Exhibit 5.42: RandD Investment Table of Top Indian Pharmaco's 2010 Vs 2013 69
Exhibit 5.43: Investments, Acquisitions and Joint Ventures Between International and Indian Pharmacos 70
Exhibit 6.1: Aurobindo Pharma Therapeutic Areas of Interest 71
Exhibit 6.2: Aurobindo Pharma Formulation Unit Accreditation 71
Exhibit 6.3: Aurobindo Pharma Range of Anti-Infective Formulations 71
Exhibit 6.4: Aurobindo Pharma Therapeutic Areas of Interest 72
Exhibit 6.5: Aurobindo Pharma Antiretroviral Therapeutic Product Portfolio 72
Exhibit 6.6: Aurobindo Pharma Antiosteoporotic Therapeutic Product Portfolio 72
Exhibit 6.7: Aurobindo Pharma Antihypertensive Therapeutic Product Portfolio 73
Exhibit 6.8: Aurobindo Pharma Antiasthmatic Therapeutic Product Portfolio 73
Exhibit 6.9: Aurobindo Pharma Beta-Lactam-Antibiotic Product Portfolio 73
Exhibit 6.10: Aurobindo Pharma Anti Erectile Dysfunction Product Portfolio 73
Exhibit 6.11: Aurobindo Pharma Antiosteoporotic Product Portfolio 73
Exhibit 6.12: Aurobindo Pharma Alzheimer's Product Portfolio 73
Exhibit 6.13: Aurobindo Pharma Antibiotic Product Portfolio 73
Exhibit 6.14: Aurobindo Pharma Antidepressant Product Portfolio 74
Exhibit 6.15: Aurobindo Pharma Antidiabetic Product Portfolio 74
Exhibit 6.16: Aurobindo Pharma Antiemetic Product Portfolio 74
Exhibit 6.17: Aurobindo Pharma Antiepileptic Therapeutic Portfolio 74
Exhibit 6.18: Aurobindo Pharma Cardiovascular Therapeutic Portfolio 75
Exhibit 6.19: Aurobindo Pharma CNS Therapeutic Portfolio 75
Exhibit 6.20: Aurobindo Pharma Pain Management Therapeutic Portfolio 75
Exhibit 6.21: Aurobindo Pharma Consolidated Revenue FY2010-FY2013 77
Exhibit 6.22: Aurobindo Pharma Revenue Breakdown: Formulation and API Sales FY2013 77
Exhibit 6.23: Aurobindo Pharma Subsidiary Companies 78
Exhibit 6.24: Aurobindo Pharma Long Term Growth Strategies 79
Exhibit 6.25: Bharat Serums and Vaccines Significant Milestones 80
Exhibit 6.26: Bharat Serums and Vaccines Range of Products 80
Exhibit 6.27: Bharat Serums and Vaccines Plasma Serum Product Portfolio 80
Exhibit 6.28: Bharat Serums and Vaccines Monoclonal Antibody Product Portfolio 80
Exhibit 6.29: Bharat Serums and Vaccines Equine Antitoxin and Serum Product Portfolio 80
Exhibit 6.30: Bharat Serums and Vaccines Cardiovascular Product Portfolio 80
Exhibit 6.31: Bharat Serums and Vaccines Anti-microbial Product Portfolio 81
Exhibit 6.32: Bharat Serums and Vaccines Anti-fungal Product Portfolio 81
Exhibit 6.33: Bharat Serums and Vaccines Anaesthesia Product Portfolio 81
Exhibit 6.34: Bharat Serums and Vaccines Hormone Product Portfolio 81
Exhibit 6.35: Biocon Biopharmaceuticals Business Outline 82
Exhibit 6.36: Biocon Biopharmaceuticals Five Key Business Areas 82
Exhibit 6.37: Biocon Biopharmaceuticals Subsidiary Companies 82
Exhibit 6.38: Biocon Biopharmaceuticals Important Milestones 83
Exhibit 6.39: Biocon Biopharmaceuticals Active Pharmaceutical Ingredients (APIs) Product Areas 84
Exhibit 6.40: Biocon Biopharmaceuticals Active Biological Product Areas 84
Exhibit 6.41: Biocon Biopharmaceuticals Diabetes Branded Formulations 85
Exhibit 6.42: Biocon Biopharmaceuticals Oncology Branded Therapeutics 85
Exhibit 6.43: Biocon Biopharmaceuticals Nephrology Branded Therapeutics 85
Exhibit 6.44: Biocon Biopharmaceuticals Cardiology Branded Therapeutics 86
Exhibit 6.45: Biocon Biopharmaceuticals Comprehensive Care Branded Therapeutics 86
Exhibit 6.46: Biocon Biopharmaceuticals Immunotherapy Branded Therapeutics 86
Exhibit 6.47: Biocon Biopharmaceuticals BioTherapy Branded Therapeutics 86
Exhibit 6.48: Biocon Biopharmaceuticals - Syngene Service Platform 88
Exhibit 6.49: Biocon Biopharmaceuticals - Clinigene Service Platform 88
Exhibit 6.50: Biocon Biopharmaceuticals Revenue 2008-2014 89
Exhibit 6.51: Biocon Biopharmaceuticals Revenue 2008-2014 89
Exhibit 6.52: Biocon Biopharmaceuticals Profits from Operations 2008-2014 89
Exhibit 6.53: Biocon Biopharmaceuticals Profits from Operations 2008-2014 90
Exhibit 6.54: Cipla Important Milestones 90
Exhibit 6.55: Cipla Main Therapeutics Areas of Interest 91
Exhibit 6.56: Cipla Export Market Share FY2012-2013 92
Exhibit 6.57: Cipla Sales and Other Income Exhibits 2003-2013 92
Exhibit 6.58: Cipla Profit after Tax Figures 2003-2013 93
Exhibit 6.59: Cipla Significant Product Launches 93
Exhibit 6.60: Cipla Significant Active Pharmaceutical Ingredient Commercialisation Launches 94
Exhibit 6.61: Divis Laboratories Important Milestones 94
Exhibit 6.62: Divis Laboratories Product Category Portfolio 95
Exhibit 6.63: Divis Laboratories Product List 95
Exhibit 6.64: Divis Laboratories Income From Operations 2006-2013 96
Exhibit 6.65: Divis Laboratories Future Pipeline Portfolio 96
Exhibit 6.66: Dr Reddy's Therapeutic Areas of Interest 97
Exhibit 6.67: Dr Reddy's Laboratories - Important Milestones 97
Exhibit 6.68: Dr Reddy's Labs Top Active Pharmaceutical Ingredients 98
Exhibit 6.69: Dr Reddy's Labs Top Brands in India 98
Exhibit 6.70: Dr Reddy's Laboratories Annual Revenue Figures 2003-2014 99
Exhibit 6.71: Dr Reddy's Laboratories Historical Revenue Figures 2006-2014 (Global) 99
Exhibit 6.72: Dr Reddy's Laboratories Geographical Revenue Percentage 100
Exhibit 6.73: Dr Reddy's Key Brand Revenue in Russia 2011-2012 100
Exhibit 6.74: Dr Reddy's Key Brand Revenue in India 2011-2012 100
Exhibit 6.75: Dr Reddy's Therapeutic Agents and Classes undergoing Clinical Trials 101
Exhibit 6.76: Lupin Significant Milestones 102
Exhibit 6.77: Lupin Ltd Formulations Product Portfolio 103
Exhibit 6.78: Lupin Ltd Active Pharmaceutical Ingredient Product Portfolio 105
Exhibit 6.79: Lupin Ltd Formulation and Active Pharmaceutical Ingredient Business Contribution 106
Exhibit 6.80: Lupin Ltd Formulations and Active Pharmaceutical Ingredient Exports 2006-2012 106
Exhibit 6.81: Lupin Ltd Formulation and Active Pharmaceutical Ingredient Revenue Contribution 107
Exhibit 6.82: Lupin Ltd Geographic Breakdown of Revenue 107
Exhibit 6.83: Lupin Ltd Net Global Sales 2008-2014 107
Exhibit 6.84: Lupin Ltd Profit Before Tax 2008-2013 108
Exhibit 6.85: Lupin Ltd Formulation Sales 2006-2013 Indian Market 108
Exhibit 6.86: Lupin Ltd Top Product Brands in the Indian Market and Ranking 109
Exhibit 6.87: Lupin Ltd Therapeutic Area Growth Increase in Comparison to Overall Market Growth 109
Exhibit 6.88: Lupin Pharma Key Products and Rank in the Indian Market 109
Exhibit 6.89: Lupin Respira Key Products and Rank in the Indian Market 109
Exhibit 6.90: Lupin Endeavour Key Products and Rank in the Indian Market 110
Exhibit 6.91: Lupin Maxter Key Products and Rank in the Indian Market 110
Exhibit 6.92: Lupin Pinnacle CVS Key Products and Rank in the Indian Market 110
Exhibit 6.93: Lupin Diabetes Care Key Products and Rank in the Indian Market 110
Exhibit 6.94: Lupin Mindvision Key Products and Rank in the Indian Market 110
Exhibit 6.95: Lupin Ikonic Key Products and Rank in the Indian Market 110
Exhibit 6.96: Lupin Pharmaceuticals Formulation Sales US Market 2007-2013 111
Exhibit 6.97: Lupin Ltd Performance in Top Five Generic Pharmaceutical Companies in the US Market 111
Exhibit 6.98: Lupin Ltd Percentage Market Share within US Generics Market 112
Exhibit 6.99: Lupin Ltd (Kyowa Pharmaceutical) Sales in Japanese Market 2008-2014 112
Exhibit 6.100: Lupin Ltd Division of Sales by Therapeutic Area 113
Exhibit 6.101: Lupin Ltd Advanced Drug Delivery System Platform Portfolio 113
Exhibit 6.102: Lupin Ltd Research and Development Areas of Expertise 113
Exhibit 6.103: Mankind Pharma Company Divisions 114
Exhibit 6.104: Mankind Pharma Key Milestones 114
Exhibit 6.105: Mankind Pharma Therapeutic Areas of Interest 115
Exhibit 6.106: Mankind Pharma Prescription Product Areas 115
Exhibit 6.107: Mankind Pharma Top Ten Brands 115
Exhibit 6.108: Mankind Pharma Diabetic Product Brands 115
Exhibit 6.109: Mankind Pharma Hyperthyroidism Product Brands 116
Exhibit 6.110: Mankind Pharma Cough Product Brands 116
Exhibit 6.111: Mankind Pharma Malaria Product Brands 116
Exhibit 6.112: Mankind Pharma Migraine Product Brands 116
Exhibit 6.113: Mankind Pharma Anti-viral Product Brands 116
Exhibit 6.114: Mankind Pharma Steroid Product Brands 116
Exhibit 6.115: Mankind Pharma Dermatology Product Brands 117
Exhibit 6.116: Mankind Pharma Ophthalmology Product Brands 117
Exhibit 6.117: Mankind Pharma Gynaecology Product Brands 117
Exhibit 6.118: Mankind Pharma Antibiotic Product Brands 118
Exhibit 6.119: Mankind Pharma Asthmatic Product Brands 118
Exhibit 6.120: Panacea Biotech Strategic Business Unit Structure 119
Exhibit 6.121: Panacea Biotech Therapeutic Areas of Interest 119
Exhibit 6.122: Panacea Biotech Leading Brands in India 119
Exhibit 6.123: Panacea Biotech Pain Management Therapy Portfolio 121
Exhibit 6.124: Panacea Biotech Diacar Alpha and Diacar Delta SBU Oral Hypoglycaemic Product Range 121
Exhibit 6.125: Panacea Biotech Diacar Alpha and Diacar Delta SBU Cardiovascular Product Range 121
Exhibit 6.126: Panacea Biotech Vaccine Portfolio 123
Exhibit 6.127: Panacea Biotech Diabetes Management Portfolio 123
Exhibit 6.128: Panacea Biotech Anti-Osteoporotic Portfolio 123
Exhibit 6.129: Panacea Biotech Antipyretic, Anti-inflammatory and Analgesic Portfolio 123
Exhibit 6.130: Panacea Biotech Renal Disease Management Portfolio 123
Exhibit 6.131: Panacea Biotech Gastro Intestinal Product Portfolio 124
Exhibit 6.132: Panacea Biotech Constipation Product Portfolio 124
Exhibit 6.133: Panacea Biotech Tuberculosis Product Portfolio 124
Exhibit 6.134: Panacea Biotech Cough/Cold Product Portfolio 124
Exhibit 6.135: Panacea Biotech Brand Standing and Market Share (India) - Diabetes and Cardiac Care 124
Exhibit 6.136: Panacea Biotech Brand Standing and Market Share (India) - Pain Management 124
Exhibit 6.137: Panacea Biotech Brand Standing and Market Share (India) - Tuberculosis Treatment 124
Exhibit 6.138: Panacea Biotech Brand Standing and Market Share (India) - Gastrointestinal Treatment 125
Exhibit 6.139: Panacea Biotech Brand Standing and Market Share (India) - Anti-Haemorrhoidal 125
Exhibit 6.140: Panacea Biotech Brand Standing and Market Share (India) - Penicillins 125
Exhibit 6.141: Panacea Biotech Current Patents for Licencing 125
Exhibit 6.142: Panacea Biotech Net Turnover 2002-2013 126
Exhibit 6.143: Panacea Biotech Net Turnover 2002-2013 126
Exhibit 6.144: Panacea Biotech Geographic Distribution of Sales, 2010-2012 126
Exhibit 6.145: Panacea Biotech Geographic Distribution of Sales, 2010-2012 127
Exhibit 6.146: Key Milestones in Piramal Group History 127
Exhibit 6.147: Piramal Distribution of Sales (Percentage) 2014 130
Exhibit 6.148: Piramal Distribution of Pharma Solutions Domestic and International Sales (Percentage) 131
Exhibit 6.149: Piramal Pharma Solutions Sales (Rs Crores) from Domestic and International Assets 131
Exhibit 6.150: Piramal Oncology Therapeutic Pipeline 132
Exhibit 6.151: Piramal Inflammation Therapeutic Pipeline 132
Exhibit 6.152: Piramal Diabetic and Metabolic Disease Therapeutic Pipeline 133
Exhibit 6.153: Piramal Infectious Disease Therapeutic Pipeline 133
Exhibit 6.154: Ranbaxy Laboratories - Therapeutic Markets of Interest 133
Exhibit 6.155: Ranbaxy's Oral Platform Technologies using a Novel Drug Delivery System 134
Exhibit 6.156: Ranbaxy Laboratories - Top Ten Therapeutics 134
Exhibit 6.157: Ranbaxy Key Merger and Acquisition Activity 135
Exhibit 6.158: List of Ranbaxy Subsidiary Companies 135
Exhibit 6.159: Ranbaxy - Future Therapeutic Areas 136
Exhibit 6.160: Ranbaxy Global Sales by Geographical Region FY2014 138
Exhibit 6.161: Ranbaxy Developed and Emerging Market Share FY2014 139
Exhibit 6.162: Ranbaxy Sales Figures, USA and Canada, FY2014 139
Exhibit 6.163: Ranbaxy Sales Figures, Western Europe FY2014 140
Exhibit 6.164: Ranbaxy Sales Figures, East Europe and CIS FY2014 140
Exhibit 6.165: Ranbaxy Top Sellers in India 141
Exhibit 6.166: Ranbaxy Sales Figures, India, 2010-2014 141
Exhibit 6.167: Ranbaxy Market Share of Top Therapeutics, India 141
Exhibit 6.168: Ranbaxy Launches by Geographical Region 141
Exhibit 6.169: Reliance Life Sciences Biopharmaceutical Product Areas 143
Exhibit 6.170: Reliance Life Sciences Pharmaceutical Product Areas 143
Exhibit 6.171: Reliance Life Sciences Clinical Research Services 143
Exhibit 6.172: Reliance Life Sciences Regenerative Medicine Product Areas 143
Exhibit 6.173: Reliance Life Sciences Molecular Medicine Product Areas 143
Exhibit 6.174: Reliance Life Science Plasma Protein Product Portfolio 143
Exhibit 6.175: Reliance Life Science Biosimilar Product Portfolio 144
Exhibit 6.176: Reliance Life Science Pharmaceutical Product Portfolio 144
Exhibit 6.177: Reliance Life Science Regenerative Medicine Product Portfolio 144
Exhibit 6.178: Reliance Life Science RandD Activities 144
Exhibit 6.179: Serum Institute of India Significant Milestones 145
Exhibit 6.180: Serum Institute of India Revenue FY2011-2013 146
Exhibit 6.181: Serum Institute of India Manufactured Products 146
Exhibit 6.182: Serum Institute of India Marketed Products 147
Exhibit 6.183: Serum Institute of India Exported Products 147
Exhibit 6.184: Serum Institute of India Product Pipeline 148
Exhibit 6.185: Sun Pharmaceuticals Revenue Stream by Formulation, Generics and API's 2013-2014 149
Exhibit 6.186: Sun Pharmaceuticals Revenue Stream by Formulation, Generics and API's 2011-2012 149
Exhibit 6.187: Sun Pharmaceuticals - Important Milestones 150
Exhibit 6.188: Sun Pharmaceutical Revenue Stream 2011-2012 ($ Millions) 151
Exhibit 6.189: Sun Pharmaceuticals Percentage Breakdown of Therapeutic Area Sales 2013-2014 152
Exhibit 6.190: Sun Pharmaceuticals Percentage Breakdown of Therapeutic Area Sales 2012-2013 152
Exhibit 6.191: Sun Pharmaceuticals Top Ten Branded Generics in India 153
Exhibit 6.192: Sun Pharmaceuticals Number of Drug Approvals by Therapeutic Area 153
Exhibit 6.193: Zydus Research Centre Speciality Areas of Research 155
Exhibit 6.194: Zydus Cadila Vaccine RandD Areas of Research 155
Exhibit 6.195: Zydus Cadila Global ‘Beyond the Billion' Business Development Strategy 156
Exhibit 6.196: Zydus Cadila Top Formulation Brands in the Indian Market 156
Exhibit 6.197: Zydus Cadila New Molecular Entities in Development Pipeline 157
Exhibit 6.198: Zydus Cadila Biosimilar Therapeutics in Development Pipeline 157
Exhibit 6.199: Zydus Cadila Indian Formulation Market Distribution (%) by Therapeutic Area 2014 159
Exhibit 6.200: Zydus Cadila Gross Sales FY2012-FY2014 159
Exhibit 6.201: Zydus Cadila List of Subsidiary Companies 160
Exhibit 6.202: Zydus Cadila Key Acquisitions 1995-2012 160
Exhibit 6.203: Zydus Cadila Research and Development Areas of Interest 160
Exhibit 7.1: Main Growth Factors of the Indian Pharmaceutical Market 161
Exhibit 7.2: Indian Health Insurance Coverage Statistics 2010-2020 161
Exhibit 7.3: Demand Drivers of the Indian Pharmaceutical Industry 163
Exhibit 7.4: Strengths of the Indian Pharmaceutical Market 164
Exhibit 7.5: Weaknesses of the Indian Pharmaceutical Market 164
Exhibit 7.6: Opportunities within the Indian Pharmaceutical Market 166
Exhibit 7.7: Threats to the Indian Pharmaceutical Market 166
Exhibit 8.1: Aurobindo Pharma Key Contact Details 167
Exhibit 8.2: Aurobindo Pharma Board of Directors and Key Personnel 167
Exhibit 8.3: Bharat Serums and Vaccines Ltd General Contact Details 168
Exhibit 8.4: Bharat Serums and Vaccines Ltd Board of Directors 168
Exhibit 8.5: Biocon Biopharmaceuticals Key Contact Details 169
Exhibit 8.6: Biocon Biopharmaceuticals Board of Directors 170
Exhibit 8.7: Biocon Biopharmaceuticals Key Management Team 170
Exhibit 8.8: Cipla Executive Directors 171
Exhibit 8.9: Cipla Non-Executive/Independent Directors 171
Exhibit 8.10: Cipla Corporate Contact Details 171
Exhibit 8.11: Divis Laboratories Key Contact Details 171
Exhibit 8.12: Divis Laboratories Key People 173
Exhibit 8.13: Dr Reddy's Laboratories Contact Information 173
Exhibit 8.14: Dr Reddy's Laboratories Key People 174
Exhibit 8.15: Dr Reddy's Laboratories Board of Directors 174
Exhibit 8.16: Dr Reddy's Audit Committee Members 175
Exhibit 8.17: Dr Reddy's Nomination, Governance and Compensation Committee Members 175
Exhibit 8.18: Dr Reddy's Risk Management Committee Members 175
Exhibit 8.19: Dr Reddy's Science, Technology and Operations Committee Members 175
Exhibit 8.20: Dr Reddy's Shareholders' Grievance Committee Members 175
Exhibit 8.21: Dr Reddy's Investment Committee Members 175
Exhibit 8.22: Dr Reddy's Management Committee Members 175
Exhibit 8.23: Lupin Board of Directors 175
Exhibit 8.24: Lupin Key Management Players 176
Exhibit 8.25: Lupin Ltd General Contact Details 176
Exhibit 8.26: Panacea Biotech - Whole Time Directors 176
Exhibit 8.27: Panacea Biotech - Independent Directors 176
Exhibit 8.28: Panacea Biotech - Investor Contact Details 177
Exhibit 8.29: Panacea Biotech - General Contact Details 177
Exhibit 8.30: Reliance Life Sciences - General Contact Details 178

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Atrial Fibrillation - Global Drug Forecast and Market Analysis to 2025 Summary Atrial fibrillation (AF) is the most common cardiac arrhythmia and is a heart condition that causes an irregula ...

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2025 Summary Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.